Literature DB >> 15862515

Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.

Cristina Cosi1, Aurelie Waget, Karin Rollet, Valentina Tesori, Adrian Newman-Tancredi.   

Abstract

Excessive activation of non-NMDA receptors, AMPA and kainate, contributes to neuronal degeneration in acute and progressive pathologies, possibly including schizophrenia. Because 5-HT(1A) receptor agonists have neuroprotective properties (e.g., against NMDA-induced neurotoxicity), we compared the effects of the antipsychotics, clozapine, ziprasidone and aripiprazole, that are partial agonists at 5-HT(1A) receptor, with those of haloperidol, which is devoid of 5-HT(1A) agonist properties, on kainic acid (KA)-induced striatal lesion volumes, in C57Bl/6N mice. The involvement of 5-HT(1A) receptors was determined by antagonist studies with WAY100635, and data were compared with those obtained using the potent and high efficacy 5-HT(1A) receptor agonist, F13714. Intra-striatal KA lesioning and measurement of lesion volumes using cresyl violet staining were carried out at 48 h after surgery. F13714, antipsychotics or vehicle were administered ip twice, 30 min before and 3 1/2 h after KA injection. WAY100635 (0.63 mg/kg) or vehicle were given sc 30 min before each drug injection. Clozapine (2 x 10 mg/kg), ziprasidone (2 x 20 mg/kg) and aripiprazole (2 x 10 mg/kg) decreased lesion volume by 61%, 59% and 73%, respectively. WAY100635 antagonized the effect of ziprasidone and of aripiprazole but only slightly attenuated that of clozapine. In contrast, haloperidol (2 x 0.16 mg/kg) did not affect KA-induced lesion volume. F13714 dose-dependently decreased lesion volume. The 61% decrease of lesion volume obtained with F13714 (2 x 0.63 mg/kg) was antagonized by WAY100635. WAY100635 alone did not affect lesion volume. These results show that 5-HT(1A) receptor activation protects against KA-induced striatal lesions and indicate that some atypical antipsychotic agents with 5-HT(1A) agonist properties may protect against excitotoxic injury, in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15862515     DOI: 10.1016/j.brainres.2005.02.072

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence.

Authors:  Mahendra Bishnoi; Kanwaljit Chopra; Lu Rongzhu; Shrinivas K Kulkarni
Journal:  Neurotox Res       Date:  2010-11-13       Impact factor: 3.911

Review 2.  Pharmacological and nonpharmacological management of delirium in critically ill patients.

Authors:  Dustin M Hipp; E Wesley Ely
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Brain differences in first-episode schizophrenia treated with quetiapine: a deformation-based morphometric study.

Authors:  Chunlan Yang; Shuicai Wu; Wangsheng Lu; Yanping Bai; Hongjian Gao
Journal:  Psychopharmacology (Berl)       Date:  2014-08-02       Impact factor: 4.530

4.  Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain.

Authors:  Nina Segnitz; Thomas Ferbert; Andrea Schmitt; Peter Gass; Peter J Gebicke-Haerter; Mathias Zink
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

Review 5.  Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Authors:  Christoph U Correll; Marta Hauser; Andrea M Auther; Barbara A Cornblatt
Journal:  J Child Psychol Psychiatry       Date:  2010-02-26       Impact factor: 8.982

6.  Effects of aripiprazole and clozapine on the treatment of glycolytic carbon in PC12 cells.

Authors:  Akira Ota; Akira Nakashima; Yoko S Kaneko; Keiji Mori; Hiroshi Nagasaki; Takeshi Takayanagi; Mitsuyasu Itoh; Kazunao Kondo; Toshiharu Nagatsu; Miyuki Ota
Journal:  J Neural Transm (Vienna)       Date:  2012-03-04       Impact factor: 3.575

7.  Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.

Authors:  Arlene D Stark; Shaun Jordan; Kelly A Allers; Robert L Bertekap; Ruoyan Chen; Tanaz Mistry Kannan; Thaddeus F Molski; Frank D Yocca; Trevor Sharp; Tetsuro Kikuchi; Kevin D Burris
Journal:  Psychopharmacology (Berl)       Date:  2006-11-25       Impact factor: 4.530

Review 8.  Aripiprazole: a review of its use in the management of schizophrenia in adults.

Authors:  Jamie D Croxtall
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

9.  Administration of mesenchymal stem cells and ziprasidone enhanced amelioration of ischemic brain damage in rats.

Authors:  Phatcharida Kaengkan; Seung Eun Baek; Ji Yeong Kim; Kyung-Yoon Kam; Byung-Rok Do; Eun Shin Lee; Sung Goo Kang
Journal:  Mol Cells       Date:  2013-11-28       Impact factor: 5.034

Review 10.  Antipsychotic treatment modulates glutamate transport and NMDA receptor expression.

Authors:  Mathias Zink; Susanne Englisch; Andrea Schmitt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-12       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.